TABLE 2.

Clinical Practice Recommendations Commenting on the Use of Metformin for the Prevention of Type 2 Diabetes, 2013–2018, Listed From Most Recent

Organization, YearName of Recommendation or GuidelineRecommendations Related to Metformin
American Diabetes Association, 2018 (23)5. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes—2018Metformin therapy for prevention of type 2 diabetes should be considered in those with prediabetes, especially those with BMI ≥35 kg/m2, those aged <60 years, and women with prior gestational diabetes.
International Diabetes Federation, 2016 (25)Cost-Effective Solutions for the Prevention of Type 2 DiabetesMetformin is an inexpensive drug for the management of type 2 diabetes and can provide sustainable health gains. It could be considered as a cost-effective strategy for type 2 diabetes prevention, alongside comprehensive lifestyle programs.
Canadian Diabetes Association, 2013 (29)2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Reducing the Risk of Developing DiabetesIn individuals with IGT, pharmacological therapy with metformin may be used to reduce the risk of type 2 diabetes.
IMAGE Project (European multidisciplinary consortium), 2010 (30)A European Evidence-Based Guideline for the Prevention of Type 2 DiabetesIn people with IGT, metformin can be used as a second-line strategy for prevention of type 2 diabetes, provided that the drug’s tolerability (gastrointestinal side effects) and contraindications (kidney, liver diseases, hypoxic conditions) are considered.
Diabetes Australia, 2009 (31)National Evidence Based Guideline for the Primary Prevention of Type 2 DiabetesPharmacological interventions are effective in preventing/delaying the onset of type 2 diabetes in high-risk individuals. Pharmacological interventions could be considered in people at high risk of developing type 2 diabetes. Metformin is a cost-effective pharmacological intervention in people at high-risk of developing diabetes.